vs
Medpace Holdings, Inc.（MEDP）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是Medpace Holdings, Inc.的1.8倍（$1.2B vs $708.5M），Medpace Holdings, Inc.净利率更高（19.1% vs -2.2%，领先21.3%），Medpace Holdings, Inc.同比增速更快（32.0% vs -18.3%），ROKU, INC自由现金流更多（$298.4M vs $188.1M），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 13.6%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
MEDP vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.8倍
$708.5M
营收增速更快
MEDP
高出50.3%
-18.3%
净利率更高
MEDP
高出21.3%
-2.2%
自由现金流更多
ROKU
多$110.3M
$188.1M
两年增速更快
MEDP
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $1.2B |
| 净利润 | $135.1M | $-27.4M |
| 毛利率 | — | 35.6% |
| 营业利润率 | 21.6% | 59.7% |
| 净利率 | 19.1% | -2.2% |
| 营收同比 | 32.0% | -18.3% |
| 净利润同比 | 15.5% | -361.0% |
| 每股收益（稀释后） | $4.65 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPROKU
| Q1 26 | — | $1.2B | ||
| Q4 25 | $708.5M | $1.4B | ||
| Q3 25 | $659.9M | $1.2B | ||
| Q2 25 | $603.3M | $1.1B | ||
| Q1 25 | $558.6M | $1.0B | ||
| Q4 24 | $536.6M | $1.2B | ||
| Q3 24 | $533.3M | $1.1B | ||
| Q2 24 | $528.1M | $968.2M |
净利润MEDPROKU
| Q1 26 | — | $-27.4M | ||
| Q4 25 | $135.1M | $80.5M | ||
| Q3 25 | $111.1M | $24.8M | ||
| Q2 25 | $90.3M | $10.5M | ||
| Q1 25 | $114.6M | $-27.4M | ||
| Q4 24 | $117.0M | $-35.5M | ||
| Q3 24 | $96.4M | $-9.0M | ||
| Q2 24 | $88.4M | $-34.0M |
毛利率MEDPROKU
| Q1 26 | — | 35.6% | ||
| Q4 25 | — | 43.5% | ||
| Q3 25 | — | 43.4% | ||
| Q2 25 | — | 44.8% | ||
| Q1 25 | — | 43.6% | ||
| Q4 24 | — | 42.7% | ||
| Q3 24 | — | 45.2% | ||
| Q2 24 | — | 43.9% |
营业利润率MEDPROKU
| Q1 26 | — | 59.7% | ||
| Q4 25 | 21.6% | 4.7% | ||
| Q3 25 | 21.5% | 0.8% | ||
| Q2 25 | 20.9% | -2.1% | ||
| Q1 25 | 20.3% | -5.7% | ||
| Q4 24 | 23.4% | -3.3% | ||
| Q3 24 | 21.1% | -3.4% | ||
| Q2 24 | 19.9% | -7.4% |
净利率MEDPROKU
| Q1 26 | — | -2.2% | ||
| Q4 25 | 19.1% | 5.8% | ||
| Q3 25 | 16.8% | 2.0% | ||
| Q2 25 | 15.0% | 0.9% | ||
| Q1 25 | 20.5% | -2.7% | ||
| Q4 24 | 21.8% | -3.0% | ||
| Q3 24 | 18.1% | -0.9% | ||
| Q2 24 | 16.7% | -3.5% |
每股收益（稀释后）MEDPROKU
| Q1 26 | — | $0.57 | ||
| Q4 25 | $4.65 | $0.55 | ||
| Q3 25 | $3.86 | $0.16 | ||
| Q2 25 | $3.10 | $0.07 | ||
| Q1 25 | $3.67 | $-0.19 | ||
| Q4 24 | $3.67 | $-0.24 | ||
| Q3 24 | $3.01 | $-0.06 | ||
| Q2 24 | $2.75 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $2.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $2.7B |
| 总资产 | $2.0B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPROKU
| Q1 26 | — | $2.4B | ||
| Q4 25 | $497.0M | $2.3B | ||
| Q3 25 | $285.4M | $2.3B | ||
| Q2 25 | $46.3M | $2.3B | ||
| Q1 25 | $441.4M | $2.3B | ||
| Q4 24 | $669.4M | $2.2B | ||
| Q3 24 | $656.9M | $2.1B | ||
| Q2 24 | $510.9M | $2.1B |
股东权益MEDPROKU
| Q1 26 | — | $2.7B | ||
| Q4 25 | $459.1M | $2.7B | ||
| Q3 25 | $293.6M | $2.6B | ||
| Q2 25 | $172.4M | $2.6B | ||
| Q1 25 | $593.6M | $2.5B | ||
| Q4 24 | $825.5M | $2.5B | ||
| Q3 24 | $881.4M | $2.5B | ||
| Q2 24 | $763.6M | $2.4B |
总资产MEDPROKU
| Q1 26 | — | $4.4B | ||
| Q4 25 | $2.0B | $4.4B | ||
| Q3 25 | $1.8B | $4.4B | ||
| Q2 25 | $1.6B | $4.3B | ||
| Q1 25 | $1.9B | $4.2B | ||
| Q4 24 | $2.1B | $4.3B | ||
| Q3 24 | $2.1B | $4.3B | ||
| Q2 24 | $1.9B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $199.1M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $298.4M |
| 自由现金流率自由现金流/营收 | 26.6% | 23.9% |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $640.0M |
8季度趋势，按日历期对齐
经营现金流MEDPROKU
| Q1 26 | — | $199.1M | ||
| Q4 25 | $192.7M | $107.7M | ||
| Q3 25 | $246.2M | $127.6M | ||
| Q2 25 | $148.5M | $109.7M | ||
| Q1 25 | $125.8M | $138.7M | ||
| Q4 24 | $190.7M | $79.3M | ||
| Q3 24 | $149.1M | $68.7M | ||
| Q2 24 | $116.4M | $23.4M |
自由现金流MEDPROKU
| Q1 26 | — | $298.4M | ||
| Q4 25 | $188.1M | $106.6M | ||
| Q3 25 | $235.5M | $126.5M | ||
| Q2 25 | $142.4M | $108.6M | ||
| Q1 25 | $115.8M | $136.8M | ||
| Q4 24 | $183.0M | $76.8M | ||
| Q3 24 | $138.5M | $67.6M | ||
| Q2 24 | $103.5M | $22.5M |
自由现金流率MEDPROKU
| Q1 26 | — | 23.9% | ||
| Q4 25 | 26.6% | 7.6% | ||
| Q3 25 | 35.7% | 10.4% | ||
| Q2 25 | 23.6% | 9.8% | ||
| Q1 25 | 20.7% | 13.4% | ||
| Q4 24 | 34.1% | 6.4% | ||
| Q3 24 | 26.0% | 6.4% | ||
| Q2 24 | 19.6% | 2.3% |
资本支出强度MEDPROKU
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 0.1% | ||
| Q3 25 | 1.6% | 0.1% | ||
| Q2 25 | 1.0% | 0.1% | ||
| Q1 25 | 1.8% | 0.2% | ||
| Q4 24 | 1.4% | 0.2% | ||
| Q3 24 | 2.0% | 0.1% | ||
| Q2 24 | 2.4% | 0.1% |
现金转化率MEDPROKU
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 1.34× | ||
| Q3 25 | 2.22× | 5.14× | ||
| Q2 25 | 1.65× | 10.45× | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
ROKU
| Advertising | $612.7M | 49% |
| Subscriptions | $518.5M | 42% |
| Devices | $117.6M | 9% |
